Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 14.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 148,200 shares, a decline of 14.8% from the November 15th total of 173,900 shares. Based on an average daily volume of 90,200 shares, the short-interest ratio is currently 1.6 days. Approximately 3.0% of the shares of the company are sold short.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI traded down $0.06 during mid-day trading on Friday, reaching $1.45. The stock had a trading volume of 46,458 shares, compared to its average volume of 61,048. The business has a fifty day moving average of $1.71 and a 200 day moving average of $3.91. The firm has a market cap of $8.27 million, a price-to-earnings ratio of -0.30 and a beta of 0.36. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.89.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.